ITRM logo

Iterum Therapeutics plc Stock Price

NasdaqCM:ITRM Community·US$26.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

ITRM Share Price Performance

US$0.60
-0.80 (-56.79%)
US$0.60
-0.80 (-56.79%)
Price US$0.60

ITRM Community Narratives

There are no narratives available yet.

Snowflake Analysis

High growth potential with moderate risk.

5 Risks
2 Rewards

Iterum Therapeutics plc Key Details

US$0

Revenue

US$941.0k

Cost of Revenue

-US$941.0k

Gross Profit

US$23.1m

Other Expenses

-US$24.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 14, 2025
-0.54
0%
0%
-837.6%
View Full Analysis

About ITRM

Founded
2015
Employees
9
CEO
Corey Fishman
WebsiteView website
www.iterumtx.com

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Recent ITRM News & Updates

Recent updates

No updates